Home
overview

In recent years, the drug delivery industry has focused on the development of established drugs coming off patent. With an ever-increasing competition in the market, drug delivery companies must become more involved in the earlier stages of drug development in addition to the discovery and research of innovative new materials and technologies.

SMi’s Drug Delivery Global Summit is designed to bring together key industry leaders from the pharmaceutical, biotechnology and drug delivery fields. Providing expert opinion, the conference offers the latest discoveries and trends in transdermal, opthalmic, oral, nasal and pulmoanry delivery, nanotechnology, drug delivery design and formulation strategies. This event also offers advice on the business and management side of developing a new delivery device and successfully brining it to market.

Hear International case studies and expert perspectives from leaders in the field, including:

  • David Stern, Executive Vice President, Metabolic & Endocrinology, Serono
  • Dr Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics
  • Dr Martin Woodle, President & Chief Scientific Officer, Intradigm Corporation
  • Steven White, Senior Director, Product Development, Epic Therapeutics, Baxter Healthcare
  • Dr Tom Tice, Executive Vice President & Chief Scientific Officer, Brookwood Pharmaceuticals
  • Dr Mason Diamond, Vice President, Clinical & Regulatory Affairs, TyRx Pharma
  • Dr Luk Chui Li, Director, Global Drug Delivery, Abbott
  • Dr Jorg Rosenberg, Associate Director, Pharmaceutical Development, SOLIQS, Abbott
  • Dr Ola Nerbrink, Principal Scientist, Device Chemistry & Biology, Novo Nordisk
  • Dr David Brayden, Chairman, UK-Ireland Chapter, Controlled Release Society

Key issues that will be addressed at the conference include:

  • Novel drug delivery systems: Hear about the latest developments in drug delivery design and how to comply with Good Manufacturing Practice
  • Nanotechnology: Discover how advances in nanotechnology can advance the drug delivery industry through novel design and application
  • Targeted drug delivery: Consider how targeting drug action can revolutionise medical treatment and understand the latest developments that can make this a reality
  • Controlled Release: Appreciate the science and technology behind long-acting parenterals and the design, development and manufacturing considerations for implants and injectable formulations
  • Challenges in drug solubility and adsorption barriers: Recognise the pitfalls associated with hydrophobic drugs, their delivery and action
  • Networking opportunities: Meet the key industry leaders, make valuable contacts and learn from their experience and expertise

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Eric Tomlinson

Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics

9:10 KEYNOTE ADDRESS

Eric Tomlinson

Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics

  • An overview of the drug delivery industry
  • Delivering old drugs in new ways
  • Targeted drug delivery
  • Novel protein delivery systems
  • 9:50 OVERCOMING SOLUBILITY ISSUES IN PARENTERAL DRUG DELIVERY

    Luk Li

    Luk Li, Director, Global Drug Delivery, Abbott Laboratories

  • Lipid systems
  • Novel non-lipid solubilisers
  • Nanoparticulate systems
  • Prodrug approach
  • 10:30 Morning Coffee

    11:00 NOVEL MUCOADHESIVE POLYMERS

    David Brayden

    David Brayden, Chairman , United Kingdon-Ireland Controlled Release Society (UKICRS)

  • An overview of the need for novel muco/bioadhesive formulations
  • New in vitro models of adhesion assessment
  • Antibacterial effects of barrier-enhancing polymers
  • Polymer-conjugated cargoes for drug delivery – case studies
  • 11:40 ORAL DOSAGE FORMS

    Joerg Rosenberg

    Joerg Rosenberg, Associate Director, Pharmaceutical Development, Abbott GmbH & Co KG

  • Traditional and orally disintegrating tablets
  • The effect of microenviromental pH on stability and performance
  • Solid state chemical and/or physical stability, dissolution and or release profiles
  • Case studies
  • 12:10 Networking Lunch

    13:50 ASSESSMENT OF ORAL DELIVERY OPTIONS

    Principal Scientist

    Principal Scientist, Principal Scientist, Pharmaceutical Profiles Ltd

  • Key factors influencing absorption and bioavailability
  • Oral delivery strategies to overcome suboptimal pharmacokinetics
  • Strategies for assessing key factors within Phase I
  • Flexible clinical protocols to define NCE "developability"
  • Case studies involving molecules with complex oral biopharmaceutical properties
  • 14:30 PULMONARY DRUG DELIVERY

    Sheldon Schaffer

    Sheldon Schaffer, Head, Buisness Development, Epic Therapeutics, Subsidiary of Baxter Healthcare Corp

  • An overview of non-invasive pulmonary delivery
  • In vivo/in vitro aerosols
  • Improving the prediction of deposition/absorption
  • Case studies – a focus on insulin
  • 15:10 Afternoon Tea

    15:40 PROTEIN DELIVERY DEVICES

    Ola Nerbrink

    Ola Nerbrink, Principal Scientist, Device Chemistry & Biology, Novo Nordisk A / S

  • Types of devices
  • Formulation characteristics: pros and cons
  • Selection criteria and how to approach it
  • 16:20 TRANSDERMAL DRUG DELIVERY

    Sarah Dexter

    Sarah Dexter, Senior Scientist, 3M

  • Transdermal market trends
  • Advantages of transdermal drug delivery
  • Physical barriers to skin permeation
  • Development of passive transdermal systems
  • Active transdermal systems and emerging technology
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Seyed Moghimi

    Seyed Moghimi, Senior Lecturer, Laboratory of Molecular Tageting & Polymer Toxicology, University Of Brighton

    9:10 ADVANCES IN TUMOUR TARGETED DRUG DELIVERY SYSTEMS

    Seyed Moghimi

    Seyed Moghimi, Senior Lecturer, Laboratory of Molecular Tageting & Polymer Toxicology, University Of Brighton

  • Pathophysiological principles and physiochemical aspects of delivery systems
  • Tumour blood flow and barriers to extravasation
  • Pseudoallergic responses associated with delivery systems
  • Applying technological advances in chemistry and engineering
  • Future platforms
  • 9:50 LONG-ACTING PARENTERALS

    Tom Tice

    Tom Tice, Executive Vice President & Chief Scientific Officer, Brookwood Pharmaceuticals

  • Delivery of small molecules, peptides, and proteins for days, weeks, and months with a single administration
  • Examples of long-acting parenteral products on the market and in the clinic
  • Science and technology behind long-acting parenterals
  • Designing, developing and manufacturing injectable microparticles and injectable solid implants
  • Disclosure of a new injectable solid implant process technology that decreases implant dimensions and increases drug content
  • 10:30 Morning Coffee

    11:00 GMP-PRODUCTION OF LIPOSOMAL VACCINES AND THERAPEUTICS

    Andreas Wagner

    Andreas Wagner, Head, Liposome Technology, Polymun Scientific GmbH

  • Liposomes - a drug delivery system or a vaccine carrier?
  • Presentation of a novel liposome technology platform
  • Advantages: scalable, reproducible and aseptic production systems; the wide variety of liposomal drugs/vaccines
  • Liposome drug and vaccine examples: a look at proteins, peptides and nucleic acids
  • Preclinical and clinical data
  • 11:40 NANOPARTICULATE SYSTEMS FOR PROTEIN DELIVERY

    You-Ping Chan

    You-Ping Chan, Director, Chemistry & Analytical Research, Flamel Technologies

  • Polymer design
  • Protein association, dissociation and stability
  • Clinical experience
  • 12:20 Networking Lunch

    13:50 siRNA GENE INHIBITION THERAPEUTICS

    Martin Woodle

    Martin Woodle, President & Chief Scientific Officer, Intradigm Corporation

  • A drug delivery system to create drug agents, combination drugs and multi-targeted cocktails
  • An overview of research programmes
  • Oncology
  • Ocular diseases
  • Respiratory viral infections
  • Transplantation
  • A case study in anti-angiogenesis therapy in oncology

  • 15:10 Afternoon Tea

    15:40 WHEN DEVICES BECOME MORE THAN JUST FOR DELIVERY

    David Stern

    David Stern, Executive Vice President, Metabolic & Endocrinology, Serono Inc

  • Defending your brand with drug delivery technology – what can drug delivery technology do for a brand?
  • Extracting greater value with mature brands
  • Improved formulary and access in managed care plans in the US
  • What is important to patients and providers?
  • 16:20 COMBINATION PRODUCTS

    Mason Diamond

    Mason Diamond, Vice President, Clinical & Regulatory Affairs, TyRx Pharma

  • Combination products - what are they?
  • Advantages of this paradigm
  • Regulatory issues 101 - pathway to approval
  • Regulatory issues 102 - post-approval challenges
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Current Trends in Global Pharmaceutical Alliances: Doing the Deal
    Workshop

    Current Trends in Global Pharmaceutical Alliances: Doing the Deal

    Hilton London Kensington
    19th September 2006
    London, United Kingdom

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    Expect a warm welcome the moment you arrive at Hilton London Kensington. We’re located in the leafy district of Holland Park, 30 minutes from Heathrow Airport, with excellent transport links into Central London and three different tube lines nearby. Step inside the hotel and you’ll find stylish rooms and suites, fantastic dining and first-class facilities for business and recreation — everything you need for a remarkable stay in the capital.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.